Results from a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, suggest that the immune-suppressing drug alefacept helps preserve function of insulin-producing beta cells in people with newly diagnosed Type 1 diabetes.

The U.S. Department of Agriculture (USDA) and National Institutes of Health have partnered to add the NIH Body Weight Planner to USDA’s SuperTracker online tool as a goal-setting resource to help people achieve and stay at a healthy weight.

In the largest study to date of hearing loss among Hispanic/Latino adults in the United States, researchers have found that nearly 1 in 7 has hearing loss, a number similar to the general population prevalence.

For the first time in a lab, researchers at the National Institutes of Health found evidence supporting the commonly held belief that people with certain physiologies lose less weight than others when limiting calories.

Features updates on the NIH nutrition research community and share some of the exciting activities taking place. From training opportunities to novel research findings, the NIH Nutrition Quarterly will highlight significant nutrition happenings at NIH.

Provides registered dietitians and nutritionists interested in chronic kidney disease updates on new NKDEP diet-related materials and activities, as well as opportunities to assist NKDEP and its efforts.

In an NIH-supported clinical trial comparing three drugs for diabetic macular edma (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial.

People with type 1 diabetes who intensively control their blood glucose (blood sugar) early in their disease are likely to live longer than those who do not, according to research funded by the National Institutes of Health.

NIH-supported researchers have found six new regions in the human genome that increase susceptibility to immunoglobulin A nephropathy (IgAN), a major cause of kidney failure worldwide. The susceptibility genes are found in people of Asian and European ancestries and affect the risk of developing IgAN and the age at which disease develops.

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health (NIH). One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment.

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

More than 29 million Americans have diabetes, and about 86 million more are on the verge of the disease. People with diabetes are nearly two times more likely than people without diabetes to die from heart disease, and are also at greater risk for kidney, eye and nerve diseases, among other painful and costly complications.